Search
EN001
go.drugbank.com/drugs/DB33920ExperimentalEN001 is under investigation in clinical trial NCT07808905 (Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia (Phase 1: Open-label, Dose-escalation, Single-center ; Phase2: Randomized
Pocenbrodib
go.drugbank.com/drugs/DB21616InvestigationalPocenbrodib is under investigation in clinical trial NCT06785636 (Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617).
Muplestim
go.drugbank.com/drugs/DB12431InvestigationalMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL
Pegsitacianine
go.drugbank.com/drugs/DB19098InvestigationalPegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Pracinostat
go.drugbank.com/drugs/DB05223InvestigationalPracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with...
TS-104
go.drugbank.com/drugs/DB33943ExperimentalTS-104 is under investigation in clinical trial NCT07814248 (A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy
Myrcludex B
go.drugbank.com/drugs/DB14853InvestigationalMyrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThis approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.